Table 1.
Characteristics of 201 randomised patients with resected NSCLC treated with adjuvant pemetrexed or gemcitabine combined with platinum with or without nadroparin
| CP/CG | CP/CG + nadroparlne | Total | |
|---|---|---|---|
| No of patients | 102 | 99 | 201 |
| Gender (M/F) | 63/39 | 56/43 | 119 (59%)/82 (41%) |
| Age (median + range) | 63 (56–69) | 61 (54–67) | 62 (54–69) |
| Performance score | |||
| 0–1 | 99 | 98 | 197 (98%) |
| 2 | 3 | 1 | 4 (2%) |
| Histology | |||
| Squamous | 40 (39%) | 36 (36%) | 76 (38%) |
| Non-squamous | 62 (61%) | 63 (64%) | 125 (62%) |
| TNM stage | |||
| pT1N1 | 32 (31%) | 27 (27%) | 59 (29%) |
| pT2N0 | 6 (6%) | 3 (3%) | 9 (4%) |
| pT2N1 | 24 (24%) | 27 (27%) | 51 (25%) |
| pT3N0 | 17 (17%) | 22 (22%) | 39 (19%) |
| pT1-4N0-2 (stage IIIA) | 21 (21%) | 18 (18%) | 39 (19%) |
| pT1-4N1-3 (stage IIIB) | 2 (2%) | 2 (2%) | 4 (2%) |
| FDG-PET. O=D | |||
| SUVmax <10 | 20 | 33 | 53 (26%) |
| SUVmax ≥10 | 75 | 57 | 132 (66%) |
| NEDPAS or EARL not fulfilled | 8 | 8 | 16 (8%) |
| Surgery | |||
| (Bi)lobectomy | 81 (79%) | 77 (78%) | 158 (79%) |
| Pneumonectomy | 20 (20 %) | 22 (22%) | 42 (21%) |
| Other | 1 (1%) | 0 (0%) | 1 (<1%) |
| R0 | 98 (95%) | 94 (96%) | 192 (96%) |
| R1 | 4 (4%) | 5 (5%) | 9 (4%) |
| Time from surgery to start chemo (wk) | 5 (5–6) | 5 (5–6) | 5 (5–6) |